Figure 3

Dependency of ahrr expression on AhR signaling.

(a) ahRR mRNA levels in skin, MLN, PP and SI of WT mice (n = 4 mice) that were injected with 3MC in DMSO/olive oil (1:4 v/v) or with solvent alone. (b) Percentages of EGFP-expressing cells in peripheral LN of WT and AhRR^E/+ mice 16 h after i.p. injection of 3MC or solvent (n = 3–8). (c) Percentages of EGFP-expressing cells in peripheral LN of WT and AhRR^E/+ mice 16 h after PBS or LPS injection i.p. (n = 3–4). Data are shown as mean ± s.e.m.; significance was determined by one way ANOVA corrected for multiple comparisons by the Sidak method *p < 0.05 (AhRR^E/+/LPS vs WT), **p < 0.01 (AhRR^E/+ vs WT). (d) Percentages of EGFP-expressing cells among MHCII⁺CD11c⁺ BMDC of WT, AhR^+/+ AhRR^E/+ and AhR^−/− AhRR^E/+ mice stimulated with or w/o LPS (n = 5). Data are shown as mean ± s.e.m.; significance was determined by one way ANOVA corrected for multiple comparisons by the Sidak method, ***p < 0.001 (BMDC from AhR^+/+AhRR^E/+ vs AhR^−/−AhRR^E/+ mice). (e) Immunofluorescence analysis of skin, SI, colon and PP of AhR^+/−AhRR^E/+ and AhR^−/−AhRR^E/+ mice (bar: 200 μm) counterstained with DAPI. PP sections were additionally counterstained for B220 expression (red). Data are representative for three independent experiments (f) Percentages of EGFP-expressing cells in PP (top) and MLN (bottom) of WT, AhR^+/+AhRR^E/+ and AhR^−/−AhRR^E/+ mice in different immune cell subsets as indicated. Data are shown as mean ± s.e.m.; significance was determined by one way ANOVA corrected for multiple comparisons by the Sidak method, ***p < 0.001 (AhR^+/+AhRR^E/+ vs AhR^−/−AhRR^E/+ mice).